Pfizer Inc. (NYSE:PFE) Holdings Increased by Annex Advisory Services LLC

Annex Advisory Services LLC grew its stake in shares of Pfizer Inc. (NYSE:PFEFree Report) by 29.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,005 shares of the biopharmaceutical company’s stock after buying an additional 2,528 shares during the quarter. Annex Advisory Services LLC’s holdings in Pfizer were worth $305,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Advisor OS LLC raised its holdings in shares of Pfizer by 1.0% during the fourth quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after acquiring an additional 365 shares during the period. Safeguard Investment Advisory Group LLC raised its holdings in shares of Pfizer by 3.9% during the fourth quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after acquiring an additional 371 shares during the period. Lantz Financial LLC raised its holdings in shares of Pfizer by 1.3% during the first quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock valued at $849,000 after acquiring an additional 381 shares during the period. King Wealth Management Group raised its holdings in shares of Pfizer by 2.4% during the fourth quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock valued at $480,000 after acquiring an additional 388 shares during the period. Finally, Advance Capital Management Inc. grew its position in Pfizer by 4.0% during the fourth quarter. Advance Capital Management Inc. now owns 10,177 shares of the biopharmaceutical company’s stock valued at $293,000 after purchasing an additional 391 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, June 17th. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Morgan Stanley boosted their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Finally, Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Ten investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $35.86.

View Our Latest Stock Analysis on Pfizer

Pfizer Price Performance

NYSE:PFE traded down $0.28 during mid-day trading on Tuesday, reaching $28.08. 9,890,691 shares of the company were exchanged, compared to its average volume of 41,024,480. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $37.80. The company has a fifty day moving average of $27.72 and a 200 day moving average of $27.70. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The stock has a market cap of $159.12 billion, a PE ratio of -470.09, a PEG ratio of 1.09 and a beta of 0.70.

Pfizer (NYSE:PFEGet Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the previous year, the company earned $1.23 EPS. Pfizer’s revenue was down 19.5% on a year-over-year basis. On average, research analysts anticipate that Pfizer Inc. will post 2.37 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 14th. Investors of record on Friday, May 10th were issued a dividend of $0.42 per share. The ex-dividend date was Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 5.98%. Pfizer’s payout ratio is -2,799.53%.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.